Aligos Therapeutics
ALGS
68 hedge funds and large institutions have $484M invested in Aligos Therapeutics in 2021 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 30 increasing their positions, 10 reducing their positions, and 6 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 10
167% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 6
17% more funds holding
Funds holding: 58 → 68 (+10)
0.1% more ownership
Funds ownership: 2.83% → 2.93% (+0.1%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
12% less capital invested
Capital invested by funds: $551M → $484M (-$66.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$27.7M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$15.4M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$7.38M |
| 4 |
Morgan Stanley
New York
|
+$7.18M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$8.32M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$5.48M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$4.37M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$3.77M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$628K |
ALGS Hedge Fund Activity: Q3 2021 in Review
68 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Aligos Therapeutics (ALGS) for Q3 2021, worth a combined $484M — down 12% from $551M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new ALGS positions and 6 closed out — a net gain of 10 holders — while 30 added to existing stakes and 10 trimmed.
The largest buyer was Logos Global Management, adding an estimated $27.7M. The largest seller was VR Adviser, exiting entirely with an estimated $8.32M sold.
- 68 institutional investors held Aligos Therapeutics (ALGS) as of Q3 2021, up from 58 in Q2 2021.
- Funds reported $484M of Aligos Therapeutics stock for Q3 2021, down 12% quarter-over-quarter.
- 16 funds opened new Aligos Therapeutics positions in Q3 2021 and 6 closed out, a net change of +10 holders.
- The largest Aligos Therapeutics buyer in Q3 2021 was Logos Global Management, an estimated $27.7M added.
- The largest Aligos Therapeutics seller in Q3 2021 was VR Adviser, an estimated $8.32M sold.
Based on aggregated 13F filings for Q3 2021.